Identification of Low-Level Product-Related Variants in Filgrastim Products Presently Available in Highly Regulated Markets

BioDrugs

Volumn 30, Issue 3, 2016, Pages 233-242

  Hausberger, Anna ^a   Lamanna, William C ^a   Hartinger, Martin ^b   Seidl, Andreas ^b   Toll, Hansjoerg ^a   Holzmann, Johann ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Sandoz Biopharmaceuticals   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; BIOSIMILAR AGENT; FILGRASTIM; GLUTAMINE; METHIONINE; TRYPTOPHAN;

AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; DEAMINATION; DRUG MARKETING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MARKET; MASS SPECTROMETRY; OXIDATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STOP CODON; CHEMISTRY; PROCEDURES;

BIOSIMILAR PHARMACEUTICALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FILGRASTIM; MASS SPECTROMETRY;

EID: 84962317965     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-016-0169-2     Document Type: Article

References (43)

1. Metcalf D. The granulocyte-macrophage colony stimulating factors. Cell. 1985;43(1):5–6.
2. Nemunaitis J. A comparative review of colony-stimulating factors. Drugs. 1997;54(5):709–29.
3. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
4. Ye SG, Ding YI, Li L, et al. Colony-stimulating factors for chemotherapy-related febrile neutropenia are associated with improved prognosis in adult acute lymphoblastic leukemia. Mol Clin Oncol. 2015;3(3):730–6.
5. ® in Europe: what have we learned? Support Care Cancer. 2013;21(10):2925–32.
6. Renner P, Milazzo S, Liu JP, et al. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev. 2012;10:CD007913.
7. Verpoort K, Mohler TM. A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre. Ther Adv Med Oncol. 2012;4(6):289–93.
8. Michels SL, Barron RL, Reynolds MW, et al. Costs associated with febrile neutropenia in the US. Pharmacoeconomics. 2012;30(9):809–23.
9. Wang XJ, Lopez SE, Chan A. Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review. Crit Rev Oncol Hematol. 2015;94(2):201–12.
10. Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract. 2012;18(2):171–9.
11. European Medicines Agency [EMA]. Questions and answers on biosimilar medicines (similar biological medicinal products). London: EMA; 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf. Accessed 25 Mar 2016.
12. Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191–6.
13. US Food and Drug Administration [FDA]. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product: guidance for industry. Silver Spring: FDA; 2015. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/General/ucm444891.htm. Accessed 17 Mar 2016.
14. Blackwell K, Semiglazov V, Krasnozhon D, et al. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2015;26(9):1948–53.
15. Sagara Y, Sato K, Fukuma E, et al. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer. Jpn J Clin Oncol. 2013;43(9):865–73.
16. Brito M, Esteves S, André R, et al. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study. Support Care Cancer. 2016;24(2):597–603.
17. Waller CF, Semiglazov VF, Tjulandin S, et al. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie. 2010;33(10):504–11.
18. del GA, Eniu A, Ganea-Motan D, et al. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer. 2008;8:332.
19. Gascon P. Presently available biosimilars in hematology–oncology: G-CSF. Target Oncol. 2012;7(Suppl 1):S29–34.
20. Holzmann J, Hausberger A, Rupprechter A, et al. Top-down MS for rapid methionine oxidation site assignment in filgrastim. Anal Bioanal Chem. 2013;405(21):6667–74.
21. Berkowitz SA, Engen JR, Mazzeo JR, et al. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11(7):527–40.
22. Beck A, Wagner-Rousset E, Ayoub D, et al. Characterization of therapeutic antibodies and related products. Anal Chem. 2013;85(2):715–36.
23. Meinnel T, Mechulam Y, Blanquet S. Methionine as translation start signal: a review of the enzymes of the pathway in Escherichia coli. Biochimie. 1993;75(12):1061–75.
24. Mazel D, Pochet S, Marliere P. Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J. 1994;13(4):914–23.
25. Skrlin A, Radic I, Vuletic M, et al. Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals. 2010;38(5):557–66.
26. Sorgel F, Schwebig A, Holzmann J, et al. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. BioDrugs. 2015;29(2):123–31.
27. Hill CP, Osslund TD, Eisenberg D. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Proc Natl Acad Sci USA. 1993;90(11):5167–71.
28. Loftfield RB, Vanderjagt D. The frequency of errors in protein biosynthesis. Biochem J. 1972;128(5):1353–6.
29. Edelmann P, Gallant J. Mistranslation in E. coli. Cell. 1977;10(1):131–7.
30. Ulrich AK, Li LY, Parker J. Codon usage, transfer RNA availability and mistranslation in amino acid starved bacteria. Biochim Biophys Acta. 1991;1089(3):362–6.
31. Kramer EB, Farabaugh PJ. The frequency of translational misreading errors in E. coli is largely determined by tRNA competition. RNA. 2007;13(1):87–96.
32. Zhang Z, Shah B, Bondarenko PV. G/U and certain wobble position mismatches as possible main causes of amino acid misincorporations. Biochemistry. 2013;52(45):8165–76.
33. Parker J, Friesen JD. “Two out of three” codon reading leading to mistranslation in vivo. Mol Gen Genet. 1980;177(3):439–45.
34. Ni J, Gao M, James A, et al. Investigation into the misincorporation of norleucine into a recombinant protein vaccine candidate. J Ind Microbiol Biotechnol. 2015;42(6):971–5.
35. Bogosian G, Violand BN, Dorward-King EJ, et al. Biosynthesis and incorporation into protein of norleucine by Escherichia coli. J Biol Chem. 1989;264(1):531–9.
36. Buckingham RH, Kurland CG. Codon specificity of UGA suppressor tRNATrp from Escherichia coli. Proc Natl Acad Sci USA. 1977;74(12):5496–8.
37. Engelberg-Kulka H. UGA suppression by normal tRNA Trp in Escherichia coli: codon context effects. Nucl Acids Res. 1981;9(4):983–91.
38. Eggertsson G, Soll D. Transfer ribonucleic acid-mediated suppression of termination codons in Escherichia coli. Microbiol Rev. 1988;52(3):354–74.
39. Hirsh D, Gold L. Translation of the UGA triplet in vitro by tryptophan transfer RNA’s. J Mol Biol. 1971;58(2):459–68.
40. MacBeath G, Kast P. UGA read-through artifacts—when popular gene expression systems need a pATCH. Biotechniques. 1998;24(5):789–94.
41. US Food and Drug Administration [FDA]. Scientific considerations in demonstrating biosimilarity to a reference product. Silver Spring: FDA; 2015. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm290967.htm. Accessed 17 Mar 2016.
42. European Medicines Agency [EMA]. Grastofil: EPAR—public assessment report. London: EMA; 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002150/human_med_001688.jsp&mid=WC0b01ac058001d124. Accessed 17 Mar 2016.
43. European Medicines Agency [EMA]. Accofil: EPAR—public assessment report. London: EMA; 2014. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003956/human_med_001798.jsp&mid=WC0b01ac058001d124. Accessed 17 Mar 2016.